Partillion Technology in the News - How Can we Improve Cell Therapies? (Copy)
Read the original article at Genetic Engineering & Biotechnology News.
In an interview with Genetic Engineering & Biotechnology News Partillion Bioscience Co-Founder and Prof of Bioengineering at UCLA, Dino Di Carlo highlights how single-cell tools such as our nanovial technology play a critical role in improving cell therapies by enabling functional screening of cells.
Di Carlo points out that the ability to enrich sub-populations of cells based on their secretion properties, whether it is cytokine-secreting T cells or VEGF-secreting mesenchymal stem cells, has the potential to drastically improve both the quality and therapeutic effect of the final products.
To learn more read the full linked article.
“We think the upcoming wave in cell therapies will need to be defined in a functional manner to bring better products to the clinic.... By selecting the most functional starting cell populations, based on the amount and type of secretions, final therapeutic products may have enhanced function.”